company background image
ZEOX logo

Zeo ScientifiX OTCPK:ZEOX Stock Report

Last Price

US$2.09

Market Cap

US$13.8m

7D

-23.0%

1Y

68.5%

Updated

23 Dec, 2024

Data

Company Financials

ZEOX Stock Overview

A clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines. More details

ZEOX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Zeo ScientifiX, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Zeo ScientifiX
Historical stock prices
Current Share PriceUS$2.09
52 Week HighUS$4.73
52 Week LowUS$0.80
Beta4.85
1 Month Change-47.75%
3 Month Change-5.86%
1 Year Change68.55%
3 Year Change-63.97%
5 Year Change-65.17%
Change since IPO-65.80%

Recent News & Updates

Recent updates

Shareholder Returns

ZEOXUS BiotechsUS Market
7D-23.0%-3.8%-2.7%
1Y68.5%-2.6%23.4%

Return vs Industry: ZEOX exceeded the US Biotechs industry which returned -2.6% over the past year.

Return vs Market: ZEOX exceeded the US Market which returned 23.4% over the past year.

Price Volatility

Is ZEOX's price volatile compared to industry and market?
ZEOX volatility
ZEOX Average Weekly Movement23.8%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: ZEOX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ZEOX's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201123Ian Bothwellwww.zeoscientifix.com

Zeo ScientifiX, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines. Its lead product candidate is Zofin, an acellular biologic therapeutic derived from perinatal sources, which is in Phase I/II clinical trial to treat COVID-19, chronic obstructive pulmonary disease, and knee osteoarthritis. The company also provides Patient Pure X, an autologous blood-derived biologic technology, that is placed in the body for exosomes the cascade of cellular reprogramming and tissue repair.

Zeo ScientifiX, Inc. Fundamentals Summary

How do Zeo ScientifiX's earnings and revenue compare to its market cap?
ZEOX fundamental statistics
Market capUS$13.76m
Earnings (TTM)-US$4.54m
Revenue (TTM)US$4.80m

2.9x

P/S Ratio

-3.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ZEOX income statement (TTM)
RevenueUS$4.80m
Cost of RevenueUS$751.63k
Gross ProfitUS$4.05m
Other ExpensesUS$8.59m
Earnings-US$4.54m

Last Reported Earnings

Jul 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.69
Gross Margin84.34%
Net Profit Margin-94.65%
Debt/Equity Ratio-47.4%

How did ZEOX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 11:00
End of Day Share Price 2024/12/20 00:00
Earnings2024/07/31
Annual Earnings2023/10/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zeo ScientifiX, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research